Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapies in these patient groups. 

According to the findings, there is a hint of a minor added benefit of albiglutide plus metformin in comparison with metformin plus sulfonylurea because hypoglycaemia occurs less frequently.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/albiglutide-in-type-2-diabetes-hint-of-minor-added-benefit.6517.html